e-learning
resources
Madrid 2019
Monday, 30.09.2019
Extra-pulmonary tuberculosis and comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients
A. Galstyan (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), M. Sinitsyn (Moscow, Russian Federation), D. Ivanova (Moscow, Russian Federation), L. Slogodskay (Moscow, Russian Federation)
Source:
International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Session:
Extra-pulmonary tuberculosis and comorbidities
Session type:
Thematic Poster
Number:
2990
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Galstyan (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), M. Sinitsyn (Moscow, Russian Federation), D. Ivanova (Moscow, Russian Federation), L. Slogodskay (Moscow, Russian Federation). Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients. 2990
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019
Year: 2020
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
The tuberculosis in patients with HIV and AIDS
Source: Eur Respir J 2007; 30: Suppl. 51, 656s
Year: 2007
Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
Anti tubercular chemoprophylaxis regimens in HIV seropositives with latent tuberculosis
Source: Eur Respir J 2002; 20: Suppl. 38, 566s
Year: 2002
Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline
Source: International Congress 2019 – Tuberculosis: a public health approach
Year: 2019
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly
Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018
Year: 2019
Characteristics of tuberculosis patients co-infected with COVID-19
Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities
Year: 2021
Treatment outcomes of MDR-TB and HIV co-infection in Europe
Source: Eur Respir J, 49 (6) 1602363; 10.1183/13993003.02363-2016
Year: 2017
Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
The incidence of MDR-TB in new and retreatment cases of HIV and pulmonary tuberculosis co-infection
Source: Annual Congress 2013 –Tuberculosis: clinical aspects
Year: 2013
Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients
Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA)
Year: 2016
Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Hospitalized tuberculosis: HIV versus non-HIV patients
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
Evaluation of the multidrug resistant TB in children with HIV infection
Source: Eur Respir J 2004; 24: Suppl. 48, 439s
Year: 2004
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept